Researchers behind a personalized CRISPR therapy are planning to launch a new type of clinical trial for rare diseases. The therapy has reportedly shown promise in at least one case, but it is unclear how widely it can be applied, with some outlets suggesting that efforts to scale it up have hit obstacles. The development of this therapy is part of a broader effort to use gene editing to treat rare diseases, with various organizations and individuals working on different approaches.